{"id":"lopinavir-r","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"20-30","effect":"Lipid elevation (hypertriglyceridemia)"},{"rate":"2-5","effect":"Hepatotoxicity"},{"rate":"1-2","effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL729","moleculeType":"Small molecule","molecularWeight":"628.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir inhibits HIV protease, the enzyme responsible for cleaving viral polyproteins into functional components necessary for viral replication. Ritonavir is a potent protease inhibitor included at low dose as a pharmacokinetic booster, inhibiting cytochrome P450 metabolism and dramatically increasing lopinavir plasma concentrations. Together, they prevent production of infectious viral particles and reduce viral load in HIV-infected patients.","oneSentence":"Lopinavir/ritonavir is a protease inhibitor combination that blocks HIV protease, preventing viral polyprotein cleavage and maturation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:10.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"COVID-19 (investigational use in some settings)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02369406","phase":"PHASE2, PHASE3","title":"Early Infant HIV Treatment in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2015-05-04","conditions":"HIV, Pediatric AIDS","enrollment":67},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT05426421","phase":"","title":"Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2022-07-11","conditions":"HIV","enrollment":258},{"nctId":"NCT04466241","phase":"PHASE2, PHASE3","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-11-27","conditions":"COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":294},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT01854762","phase":"PHASE2, PHASE3","title":"Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2015-06-01","conditions":"HIV, Pregnancy","enrollment":33},{"nctId":"NCT01480713","phase":"PHASE3","title":"Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-05","conditions":"HIV-1 Infection","enrollment":41},{"nctId":"NCT04328285","phase":"PHASE3","title":"Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-04-14","conditions":"COVID-19","enrollment":118},{"nctId":"NCT04499677","phase":"PHASE2","title":"FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-24","conditions":"COVID-19","enrollment":240},{"nctId":"NCT01165645","phase":"NA","title":"Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2010-11","conditions":"Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT02712801","phase":"PHASE4","title":"Antiretroviral Regime for Viral Eradication in Newborns","status":"COMPLETED","sponsor":"National Center for Women and Children's Health, China CDC","startDate":"2016-04","conditions":"HIV/AIDS and Infections","enrollment":600},{"nctId":"NCT03603977","phase":"","title":"Simplified Treatment of Anti-retrovirus in China (C-STAR)","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2017-11-01","conditions":"HIV/AIDS","enrollment":600},{"nctId":"NCT04354428","phase":"PHASE2, PHASE3","title":"Treatment for COVID-19 in High-Risk Adult Outpatients","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-04-16","conditions":"COVID-19, SARS-CoV-2","enrollment":289},{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT04321174","phase":"PHASE3","title":"COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-04-17","conditions":"Coronavirus Infections, Post-exposure Prophylaxis","enrollment":123},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":175},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00004855","phase":"NA","title":"Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT02369965","phase":"PHASE3","title":"Test Albuvirtide in Experienced Patients","status":"COMPLETED","sponsor":"Frontier Biotechnologies Inc.","startDate":"2014-02-19","conditions":"HIV Infections, AIDS","enrollment":418},{"nctId":"NCT01818258","phase":"PHASE4","title":"IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-10-26","conditions":"HIV Positive, Malnourished","enrollment":52},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT04138199","phase":"","title":"A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-11-01","conditions":"HIV-1 Infection","enrollment":239},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01138202","phase":"PHASE2","title":"Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-11","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00627055","phase":"PHASE4","title":"Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT01159275","phase":"PHASE1, PHASE2","title":"Lopinavir (LPV) Dose Reduction","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2009-07","conditions":"HIV-1 Infections","enrollment":20},{"nctId":"NCT00281606","phase":"PHASE4","title":"A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-02-14","conditions":"HIV Infection","enrollment":65},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02415985","phase":"PHASE2","title":"Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2015-06","conditions":"HIV, Tuberculosis","enrollment":40},{"nctId":"NCT01116817","phase":"PHASE4","title":"Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2010-08","conditions":"HIV","enrollment":35},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT03836833","phase":"PHASE1, PHASE2","title":"Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2019-06-04","conditions":"HIV","enrollment":50},{"nctId":"NCT02581202","phase":"","title":"The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-21","conditions":"HIV-1 Infection","enrollment":216},{"nctId":"NCT02346487","phase":"PHASE3","title":"Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2015-09","conditions":"HIV","enrollment":1003},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT00531986","phase":"PHASE4","title":"HIV - Monotherapy in Switzerland (MOST-ch)","status":"TERMINATED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2007-01","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02671383","phase":"PHASE3","title":"Evaluation of Low-dose Darunavir in a Switch Study","status":"COMPLETED","sponsor":"Willem Daniel Francois Venter","startDate":"2016-06-30","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT02231281","phase":"PHASE3","title":"Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults","status":"UNKNOWN","sponsor":"Yongtao Sun, MD, PhD","startDate":"2014-08","conditions":"Acute HIV Infection","enrollment":65},{"nctId":"NCT00357552","phase":"NA","title":"Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2008-01","conditions":"HIV Infections","enrollment":123},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT01662336","phase":"","title":"Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":173},{"nctId":"NCT01637558","phase":"PHASE4","title":"Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2012-11","conditions":"Tuberculosis, HIV","enrollment":200},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT01905059","phase":"PHASE3","title":"Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-02","conditions":"HIV Infection","enrollment":265},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02348177","phase":"PHASE4","title":"Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2013-01","conditions":"Acquired Immunodeficiency Syndrome, Tuberculosis","enrollment":96},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452},{"nctId":"NCT01146873","phase":"PHASE3","title":"Treatment Options for Protease Inhibitor-exposed Children","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-07","conditions":"HIV/AIDS, HIV Infections","enrollment":300},{"nctId":"NCT00474201","phase":"NA","title":"Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-05","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT00719602","phase":"EARLY_PHASE1","title":"Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2009-08","conditions":"HIV Infections, Malaria","enrollment":105},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00409591","phase":"PHASE3","title":"Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand","status":"TERMINATED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2008-07","conditions":"HIV Infections, Pregnancy","enrollment":435},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01296152","phase":"PHASE2","title":"Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-05","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT00159224","phase":"PHASE4","title":"Induction-maintenance of Lopinavir/r in HIV-infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2005-04","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT00771498","phase":"PHASE4","title":"An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-11","conditions":"HIV Infection, Tuberculosis","enrollment":30},{"nctId":"NCT01227590","phase":"PHASE1","title":"Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-02","conditions":"Drug Interactions, Human Immunodeficiency Virus","enrollment":18},{"nctId":"NCT01533272","phase":"PHASE4","title":"Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2012-02","conditions":"HIV Infection","enrollment":240},{"nctId":"NCT01576731","phase":"PHASE4","title":"Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2012-07","conditions":"HIV Infection","enrollment":240},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00476359","phase":"PHASE4","title":"A PK and Salvage Study for Children With HIV-infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-10","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT01139905","phase":"PHASE2","title":"Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":24},{"nctId":"NCT00626301","phase":"PHASE4","title":"Lopinavir/Ritonavir Monotherapy in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-11","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01307124","phase":"PHASE3","title":"Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-03","conditions":"HIV-infected Children","enrollment":199},{"nctId":"NCT00023218","phase":"NA","title":"Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":""},{"nctId":"NCT00700115","phase":"PHASE4","title":"Kaletra-isentress Treatment Evaluation","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-06","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02256826","phase":"PHASE1","title":"Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT00978237","phase":"PHASE4","title":"Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-10","conditions":"HIV Infections, Lipoatrophy","enrollment":20},{"nctId":"NCT02219672","phase":"PHASE3","title":"Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2014-07","conditions":"AIDS/HIV PROBLEM","enrollment":18},{"nctId":"NCT00640263","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-12","conditions":"HIV Infections","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":100,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lopinavir/r","genericName":"Lopinavir/r","companyName":"Universidade Federal do Rio de Janeiro","companyId":"universidade-federal-do-rio-de-janeiro","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lopinavir/ritonavir is a protease inhibitor combination that blocks HIV protease to prevent viral replication. Used for HIV-1 infection (treatment), COVID-19 (investigational use during pandemic).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}